Literature DB >> 994335

Some problems in long-term prevention of streptococcal infection among children with rheumatic heart disease in Taiwan.

H C Lue, C L Chen, H Wei.   

Abstract

In Taiwan, rheumatic fever (RF) and rheumatic heart disease (RHD) remain widespread and constituting a health problem. The long-term prevention of streptococcal infections among rheumatic children has also failed to prevail, and yet has seldom been emphasized. Therefore, recurrence of RF remained prevalent. For an appraisal of the difficulties in the administration of long-term medication prophylaxis, a prospective study was started in 1967. One hundred and five consecutive cases of RF and RHD were followed up for more than 1 year to 6 years with an average of 4.4 years. One hundred and two cases received monthly injections of benzathine penicillin G for 6 months to 6 years, of whom 10 were switched to daily sulfa drugs; 1 case had oral penicillin daily for 6 years; in 12 cases, sulfa drugs were given for 6 months to 5 years. Fifty-one cases (48.6 %) stayed well in the program; 22 (21.0 %) stayed but were not compliant; 32 (30.4 %) dropped out soon or after staying in for more than 1 year. Major risk factors leading to non-compliance are; 1) apparent recovery from the illness or resumption of the normal activity; 2) cram session at school; 3) lack of easy medical care system; and 4) shortage of active participation by the health workers and general practitioners. The present study confirmed that the long-term prevention of streptococcal infection was effective and contributed to the decline of RF recurrence rate from more than 30 % down to 6%. Our study implicates that this important preventive program can not be achieved just only by the hospital staff, but should be approached jointly by all doctors, health and social workers, school teachers and the parents.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 994335     DOI: 10.1536/ihj.17.550

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  5 in total

1.  Response to Godown and Beaton-Handheld echocardiography: A new tool for rheumatic heart disease in the developing world?

Authors:  Marc G W Rémond; Graeme P Maguire
Journal:  Transl Pediatr       Date:  2015-07

Review 2.  Screening for rheumatic heart disease: current approaches and controversies.

Authors:  Kathryn Roberts; Samantha Colquhoun; Andrew Steer; Bo Reményi; Jonathan Carapetis
Journal:  Nat Rev Cardiol       Date:  2012-11-13       Impact factor: 32.419

3.  Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).

Authors:  Liesl Zühlke; Mark E Engel; Ganesan Karthikeyan; Sumathy Rangarajan; Pam Mackie; Blanche Cupido; Katya Mauff; Shofiqul Islam; Alexia Joachim; Rezeen Daniels; Veronica Francis; Stephen Ogendo; Bernard Gitura; Charles Mondo; Emmy Okello; Peter Lwabi; Mohammed M Al-Kebsi; Christopher Hugo-Hamman; Sahar S Sheta; Abraham Haileamlak; Wandimu Daniel; Dejuma Y Goshu; Senbeta G Abdissa; Araya G Desta; Bekele A Shasho; Dufera M Begna; Ahmed ElSayed; Ahmed S Ibrahim; John Musuku; Fidelia Bode-Thomas; Basil N Okeahialam; Olukemi Ige; Christopher Sutton; Rajeev Misra; Azza Abul Fadl; Neil Kennedy; Albertino Damasceno; Mahmoud Sani; Okechukwu S Ogah; Taiwo Olunuga; Huda H M Elhassan; Ana Olga Mocumbi; Abiodun M Adeoye; Phindile Mntla; Dike Ojji; Joseph Mucumbitsi; Koon Teo; Salim Yusuf; Bongani M Mayosi
Journal:  Eur Heart J       Date:  2014-11-25       Impact factor: 29.983

4.  Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.

Authors:  Shannon Marantelli; Robert Hand; Jonathan Carapetis; Andrea Beaton; Rosemary Wyber
Journal:  Heart Asia       Date:  2019-06-20

Review 5.  Rheumatic heart disease screening: Current concepts and challenges.

Authors:  Scott Dougherty; Maziar Khorsandi; Philip Herbst
Journal:  Ann Pediatr Cardiol       Date:  2017 Jan-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.